Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629087 | 0.93 | CYP1A2 (0.52) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1628808 | 0.89 | ALDH1A1 (0.42) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1628681 | 0.85 | ALPL (0.47) | ALDH1A1SMN1; SMN2LMNABRD4BRD2 | |
| SCHEMBL1628925 | 0.83 | HSP90AA1 (0.47) | CYP1A2CYP2C19SMN1; SMN2LMNAHTT | |
| SCHEMBL1628685 | 0.82 | HSP90AA1 (0.46) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1629805 | 0.82 | NR3C2 (0.41) | ALDH1A1LMNABRD4HPGDKMT2A | |
| SCHEMBL1629643 | 0.82 | NR3C2 (0.39) | CYP1A2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1631535 | 0.80 | TSHR (0.46) | CYP1A2ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1629022 | 0.78 | ALPL (0.45) | ALDH1A1BRD4BRD2BRD3KMT2A | |
| SCHEMBL1631546 | 0.75 | HSP90AA1 (0.40) | ALDH1A1SMN1; SMN2LMNAHTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | CYP1A2 445/4885CYP2C19 948/4885ALDH1A1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.